[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 50 of about 50
1. Li B, Li Z, Zhang Y, Li Y, Wu W: [Clinical analysis of surgically treated patients with adenosquamous carcinoma of the lung]. Zhongguo Fei Ai Za Zhi; 2006 Oct 20;9(5):469-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of surgically treated patients with adenosquamous carcinoma of the lung].
  • BACKGROUND: Adenosquamous carcinoma of the lung is a rare pathologic type of lung cancer.
  • The aim of this study is to explore the clinical features of adenosquamous carcinoma of the lung.
  • METHODS: A total of 115 patients with adenosquamous carcinoma of the lung were retrospectively analysed, who were diagnosed by operation and pathology.
  • There were 14 patients (12.17%) without any symptom and 16 patients had residual carcinoma at the resection margin (14.04%).
  • CONCLUSIONS: The incidence of adenosquamous carcinoma of the lung in young women (under 49 years, especially under 39 years) is rather high.
  • The residual carcinoma at the resection margin often occurs after routine operation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21176475.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


2. Kang SM, Kang HJ, Shin JH, Kim H, Shin DH, Kim SK, Kim JH, Chung KY, Kim SK, Chang J: Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. Cancer; 2007 Feb 1;109(3):581-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung.
  • BACKGROUND: Adenosquamous carcinoma of the lung is composed of adenocarcinomatous and squamous cell carcinomatous components.
  • The epidermal growth factor receptor (EGFR) mutations occur mostly in adenocarcinomas and rarely in squamous cell carcinoma of lung.
  • Attempts to investigate the EGFR mutation status in each component of adenosquamous carcinoma and to characterize the patients according to mutation status may help to understand the histogenesis of adenosquamous carcinoma.
  • METHODS: The mutation status of EGFR kinase domain from exon 18 to 21 was investigated in 25 Korean patients with adenosquamous carcinoma by polymerase chain reaction-single strand conformation polymorphism using the tissues of each component from the adenosquamous carcinoma tumor.
  • Identical EGFR mutations in both components of adenosquamous carcinoma were confirmed by nucleotide sequencing.
  • CONCLUSIONS: The frequency of EGFR mutation and clinicopathologic characteristics of the EGFR mutants in adenosquamous carcinoma are similar to those of Asian patients with adenocarcinomas.
  • Identical EGFR mutations in both components suggest the possibility of monoclonality in the histogenesis of adenosquamous carcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Adenosquamous / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Squamous Cell / genetics. Lung Neoplasms / genetics. Mutation / genetics. Receptor, Epidermal Growth Factor / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17186532.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


3. Uramoto H, Yamada S, Hanagiri T: Clinicopathological characteristics of resected adenosquamous cell carcinoma of the lung: risk of coexistent double cancer. J Cardiothorac Surg; 2010;5:92
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of resected adenosquamous cell carcinoma of the lung: risk of coexistent double cancer.
  • BACKGROUND: adenosquamous carcinoma (ADSQ) of non-small cell lung cancer (NSCLC) is a rare disease and the biological behavior and clinicopathological characteristics have not yet been thoroughly described.
  • METHOD: This study reviewed the patient charts of 11 (1.6%) ADSQ cases among 779 patients with primary lung cancer who underwent a lung resection.
  • Five patients had coexistent double cancer including 2 gastric, 1 rectal, 1 prostate and 1 bladder cancer.
  • ADSQ was found less frequently in males than squamous cell carcinoma (SQ).
  • ADSQ was found more frequently in older patients, with advanced stage, advanced T status, and lymph node metastases than adenocarcinoma (AD).
  • The proportion with coexistent double cancer of AD, SQ, and ADSQ were 21.1, 17.6, and 45.5%, respectively.
  • ADSQ had a significantly correlation with double cancer (ADSQ vs. non- ADSQ p = 0.03).
  • A multivariate analysis showed no significant prognostic difference between the patients with ADSQ and non- ADSQ.
  • CONCLUSIONS: In this study, cases with ADSQ showed no significantly prognostic difference in comparison to AD and SQ.
  • However, surgeons must be cautious of any coexistent double cancer because approximately half of all patients with ADSQ of the lung have double cancer.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1996 Apr;109(4):989-94 [8635382.001]
  • [Cites] Cancer Invest. 1993;11(6):641-51 [8221196.001]
  • [Cites] Oncol Rep. 1998 Jul-Aug;5(4):861-5 [9625833.001]
  • [Cites] Scand Cardiovasc J. 1999;33(1):29-32 [10093856.001]
  • [Cites] Respir Med. 2006 Dec;100(12):2073-84 [17056245.001]
  • [Cites] Ann Thorac Surg. 2007 Aug;84(2):702-7 [17643676.001]
  • [Cites] Med Oncol. 2009;26(1):27-31 [18483884.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1289-98 [10751354.001]
  • [Cites] Jpn J Cancer Res. 1999 Nov;90(11):1244-7 [10622536.001]
  • [Cites] Chest. 2000 Feb;117(2):374-9 [10669677.001]
  • [Cites] Ann Thorac Surg. 2003 Jun;75(6):1740-4 [12822609.001]
  • [Cites] Natl Cancer Inst Monogr. 1985 Dec;68:219-42 [4088299.001]
  • [Cites] Ann Thorac Surg. 1987 Nov;44(5):462-6 [3675050.001]
  • [Cites] Am Rev Respir Dis. 1990 Jul;142(1):19-23 [2368969.001]
  • [Cites] Cancer. 1991 Feb 1;67(3):649-54 [1985759.001]
  • [Cites] Am J Clin Pathol. 1992 May;97(5):678-85 [1575214.001]
  • [Cites] Ann Thorac Surg. 1993 Mar;55(3):593-6 [8452418.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • (PMID = 21034441.001).
  • [ISSN] 1749-8090
  • [Journal-full-title] Journal of cardiothoracic surgery
  • [ISO-abbreviation] J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit
  • [Other-IDs] NLM/ PMC2987925
  •  go-up   go-down


Advertisement
4. Spizzo G, Seeber A, Mitterer M: Routine use of pamidronate in NSCLC patients with bone metastasis: results from a retrospective analysis. Anticancer Res; 2009 Dec;29(12):5245-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: No data on the tolerability and effects of pamidronate in non-small cell lung cancer patients with bone metastasis are available.
  • CONCLUSION: The diagnosis of bone metastasis and the consequent routine administration of pamidronate have an impact on survival of NSCLC patients; this drug is a good candidate for routine use in haemato-oncological centres.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / drug therapy. Diphosphonates / therapeutic use. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20044644.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphosphonates; OYY3447OMC / pamidronate
  •  go-up   go-down


5. Damadoğlu E, Aybatli A, Yalçinsoy M, Tahaoğlu C, Atasalihi A, Akkaya E, Yilmaz A: [Adenosquamous carcinoma of the lung (an analysis of 13 cases)]. Tuberk Toraks; 2005;53(2):161-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenosquamous carcinoma of the lung (an analysis of 13 cases)].
  • Adenosquamous carcinoma of the lung is a rare disease.
  • In this study, we retrospectively evaluated 13 patients with adenosquamous carcinoma of the lung diagnosed at our center between January 2001 and May 2004.
  • Preoperative pathological diagnosis was squamous cell carcinoma in eight patients, non-small cell lung carcinoma in four patients and adenocarcinoma in one patient.
  • [MeSH-major] Carcinoma, Adenosquamous / epidemiology. Lung Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16100653.001).
  • [ISSN] 0494-1373
  • [Journal-full-title] Tüberküloz ve toraks
  • [ISO-abbreviation] Tuberk Toraks
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


6. Feng X, Li L, Gao Y, Zhang J, Ying J, Xiao T, Gao J, Liu X, Sun Y, Cheng S: Fhit protein expression in lung cancer studied by high-throughput tissue microarray. Bull Cancer; 2007 Mar;94(3):E8-11
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fhit protein expression in lung cancer studied by high-throughput tissue microarray.
  • AIM: To study the expression of Fhit protein in lung cancers and its potential relevance in the diagnosis and prognosis of lung cancers.
  • METHODS: Tissue microarrays (TMA) and Immunohistochemistry (IHC) were performed in 321 cases of lung cancers.
  • RESULTS: In our TMA blocks comprising 321 cases of lung cancer, there were 253 (78.8 %) cases valid for Fhit protein assessment.
  • Fhit protein loss in NSCLCs (non-small cell lung carcinoma was significantly lower than in SCLCs (small cell lung cancers) (p < 0.05), in most squamous cell carcinomas (85 out of 105, 81.0 %), and in a smaller portion of adenocarcinomas (53 out of 109, 48.6 %; p < 0.05).
  • CONCLUSIONS: Our studies showed that the loss or reduced expression of Fhit, a tumour suppressor gene is a frequent occurrence in lung cancers, with variations amongst different histological subtypes.
  • [MeSH-major] Acid Anhydride Hydrolases / analysis. Biomarkers, Tumor / analysis. Lung Neoplasms / chemistry. Neoplasm Proteins / analysis. Tissue Array Analysis / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / chemistry. Carcinoma, Non-Small-Cell Lung / chemistry. Carcinoma, Small Cell / chemistry. Carcinoma, Squamous Cell / chemistry. Female. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Male. Middle Aged. Reagent Kits, Diagnostic

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17371765.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Reagent Kits, Diagnostic; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


7. Sousa M, Cavadas S, Moreira MJ, Mellidez JC: Erlotinib in non-small cell lung cancer's second line treatment. Clinical case. Rev Port Pneumol; 2008 Oct;14 Suppl 3:S79-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erlotinib in non-small cell lung cancer's second line treatment. Clinical case.
  • [Transliterated title] Erlotinib no tratamento de segunda linha do cancro do pulmão de não pequenas células. Caso clínico.
  • Male, of 58 years, caucasian, construction worker, non smoker, with depressive syndrome, biliary lithiasis, renal cysts, surgery for benign intestinal polyps and relevant familiar history - aunt with lung cancer and mother with colon cancer.
  • He initiated thorax pain and vomitting and made a chest x-ray, showing a right basal lung mass.
  • During the etiologic study, he was submitted to thoracotomy with biopsy, in April 2006 - "fine granulations, spread for all the pulmonary field", allowing the diagnosis - adenosquamous lung carcinoma, stage IV (16/05/2006).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 Sociedade Portuguesa de Pneumologia/SPP.
  • (PMID = 25967692.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] eng; por
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Keywords] NOTNLM ; Lung cancer / Neoplasia do pulmão / adenosquamous carcinoma / carboplatin / carboplatino / carcinoma adenoescamoso / erlotinib / vinorelbina / vinorelbine
  •  go-up   go-down


8. Joshita S, Nakazawa K, Sugiyama Y, Kamijo A, Matsubayashi K, Miyabayashi H, Furuta K, Kitano K, Kawa S: Granulocyte-colony stimulating factor-producing pancreatic adenosquamous carcinoma showing aggressive clinical course. Intern Med; 2009;48(9):687-91
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocyte-colony stimulating factor-producing pancreatic adenosquamous carcinoma showing aggressive clinical course.
  • Herein, we encountered an 89-year-old woman with pancreatic cancer who presented with fever without infective focus, leukocytosis of 45,860 /microL, and elevation of serum granulocyte-colony stimulating factor (G-CSF).
  • Specimens taken at necropsy revealed an adenosquamous carcinoma positive for G-CSF by immunohistochemistry; it was only the second reported case to date.
  • She was finally diagnosed with G-CSF-producing pancreatic cancer.
  • In light of the above, clinicians should consider the presence of G-CSF-producing tumors, including pancreatic cancer, when presented with patients showing leukocytosis of unknown origin and fever without infective focus.
  • [MeSH-major] Carcinoma, Adenosquamous / diagnosis. Granulocyte Colony-Stimulating Factor / biosynthesis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Female. Humans. Leukocytosis / diagnosis. Leukocytosis / immunology. Lung Neoplasms / immunology. Lung Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19420814.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  • [Number-of-references] 27
  •  go-up   go-down


9. Yu JQ, Yang ZG, Austin JH, Guo YK, Zhang SF: Adenosquamous carcinoma of the lung: CT-pathological correlation. Clin Radiol; 2005 Mar;60(3):364-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the lung: CT-pathological correlation.
  • AIM: To correlate CT morphological features and histopathological findings of adenosquamous carcinoma of the lung.
  • MATERIALS AND METHODS: In all, 29 patients underwent contrast-enhanced CT of an adenosquamous carcinoma of the lung, followed by resection of the cancer.
  • These CT features corresponded mainly to solid tumour growth, which was composed of both squamous cell carcinomatous and adenocarcinomatous tissue.
  • CONCLUSION: Adenosquamous carcinoma of the lung is shown to be characteristically a solid, lobulated nodule or mass, more commonly peripheral than central.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Lung Neoplasms / pathology. Lung Neoplasms / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15710140.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Li J, Zhang DC, He J, Liu XY, Mu JW, Zhang LZ: [The rule of lymph node metastasis of adenosquamous carcinoma of the lung]. Zhonghua Zhong Liu Za Zhi; 2009 Jul;31(7):524-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The rule of lymph node metastasis of adenosquamous carcinoma of the lung].
  • OBJECTIVE: To investigate the rule of lymph node metastasis of adenosquamous carcinoma of the lung.
  • METHODS: The data of 361 surgically treated patients with adenosquamous carcinoma of the lung from October 1965 to June 2003 were collected and retrospectively reviewed.
  • The skip mediastinal lymph node metastasis but N1 negative most commonly metastasized to station 7, then to station 4 from the tumor in the right lung and 5 from the tumor in the left lung.
  • CONCLUSION: The lung cancer growing in a different location has a different route and skipping metastasis to mediastinal lymph nodes.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Lung Neoplasms / pathology. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950701.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


11. Sasaki H, Endo K, Yukiue H, Kobayashi Y, Yano M, Fujii Y: Mutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lung. Lung Cancer; 2007 Jan;55(1):129-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lung.
  • We have investigated 26 adenosquamous lung cancer tissues and found that four EGFR mutations were mainly in female and non-smoker lung cancer.
  • [MeSH-major] Carcinoma, Adenosquamous / genetics. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Lung Cancer. 2006 Apr;52(1):47-52 [16503085.001]
  • (PMID = 17156891.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comment; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


12. Diaz A, Batista AE, Montero E: Interferon-alpha conditioned sensitivity to an anti-epidermal growth factor receptor monoclonal antibody in a human lung cancer cell line with intermediate expression of the receptor. J Interferon Cytokine Res; 2009 Aug;29(8):433-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-alpha conditioned sensitivity to an anti-epidermal growth factor receptor monoclonal antibody in a human lung cancer cell line with intermediate expression of the receptor.
  • Interferon-alpha (IFN-alpha) induces growth inhibition but also may up-regulate the EGFR expression in some cancer cell lines.
  • We aimed to determine whether the IFN-alpha combined with an EGFR-specific monoclonal antibody (nimotuzumab) may affect the growth of human tumor epithelial cell lines with different EGFR expression levels.
  • H125, a lung adenosquamous carcinoma, and A431, a vulvar epidermoid carcinoma, cell lines express intermediate and high levels of EGFR, respectively, whereas MDA MB231, a breast adenocarcinoma cell line expresses undetectable levels of EGFR measured by flow cytometry/FACS.
  • We found that IFN-alpha alone inhibited in a dose-dependent fashion the growth of all cell lines, but only up-regulated the EGFR expression in the lung carcinoma-derived cell line.
  • Noteworthy, the combined treatment did not modify the complement-mediated cytotoxicity of the antibody although the antiproliferative activity of nimotuzumab in H125 cells in vitro increased when an IFN-alpha-conditioning treatment was used.
  • In conclusion, this study may provide insights about the rational use of EGFR inhibitors into the immunopharmacological management of targeted therapies including the IFN-alpha for lung cancer.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Epithelial Cells / immunology. Growth Inhibitors / metabolism. Immunologic Factors / pharmacology. Immunotherapy. Interferon-alpha / metabolism. Lung Neoplasms / immunology. Lung Neoplasms / therapy. Receptor, Epidermal Growth Factor / immunology
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Breast Neoplasms / immunology. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Breast Neoplasms / therapy. Cell Growth Processes / drug effects. Cell Line, Tumor. Cell Separation. Complement System Proteins / metabolism. Cytotoxicity, Immunologic / drug effects. Dose-Response Relationship, Immunologic. Drug Synergism. Female. Flow Cytometry. Gene Expression Regulation, Neoplastic. Humans. Vulvar Neoplasms / immunology. Vulvar Neoplasms / metabolism. Vulvar Neoplasms / pathology. Vulvar Neoplasms / therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19514842.001).
  • [ISSN] 1557-7465
  • [Journal-full-title] Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • [ISO-abbreviation] J. Interferon Cytokine Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Growth Inhibitors; 0 / Immunologic Factors; 0 / Interferon-alpha; 0 / nimotuzumab; 9007-36-7 / Complement System Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


13. Morinaga R, Matsunaga N, Iwata A, Kishi K, Tokimatsu I, Nagai H, Kadota J: [A case of diaphragmatic paralysis caused by herpes zoster after anticancer chemotherapy]. Nihon Kokyuki Gakkai Zasshi; 2007 Feb;45(2):166-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 61-year-old woman who had been followed up after resection of lung cancer (adenosquamous cell carcinoma), was admitted to our hospital because of recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Herpes Zoster / chemically induced. Herpes Zoster / complications. Respiratory Paralysis / etiology
  • [MeSH-minor] Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / surgery. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery. Lymph Node Excision. Middle Aged. Pneumonectomy. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - paralysis.
  • MedlinePlus Health Information. consumer health - Shingles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352174.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


14. Uramoto H, Yamada S, Hanagiri T: Immunohistochemical staining with deltaNp63 is useful for distinguishing the squamous cell component of adenosquamous cell carcinoma of the lung. Anticancer Res; 2010 Nov;30(11):4717-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining with deltaNp63 is useful for distinguishing the squamous cell component of adenosquamous cell carcinoma of the lung.
  • The aim of this study was to detect the deltaNp63 expression in the squamous carcinoma component of adenosquamous carcinoma and evaluate its usefulness as a specific squamous carcinoma marker.
  • PATIENTS AND METHODS: Immunohistochemistry was used to analyze the protein expression of deltaNp63 and high molecular weight cytokeratin in paraffin-embedded tumor samples from 17 patients with well-characterized adenosquamous carcinoma.
  • It was easy to discriminate the squamous carcinoma and adenocarcinoma components in all tumors.
  • CONCLUSION: These findings indicated that the deltaNp63 status was useful for distinguishing squamous carcinoma from adenocarcinoma in formalin-postfixed adenosquamous carcinoma specimens.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Adenosquamous / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / metabolism. Lung Neoplasms / metabolism. Trans-Activators / metabolism. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21115930.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


15. Otrock ZK, Mahfouz RA, Salem ZM: Four primary tumors of lung, bladder, prostate, and breast in a male patient. South Med J; 2005 Sep;98(9):946-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four primary tumors of lung, bladder, prostate, and breast in a male patient.
  • Immunohistochemical stains showed tumor cell nuclei to be negative for p53 over-expression.
  • The tumors included an adenosquamous cell carcinoma of the lung, transitional cell carcinoma of the urinary bladder, and adenocarcinomas of the prostate and the breast.
  • [MeSH-major] Breast Neoplasms / complications. Carcinoma / complications. Lung Neoplasms / complications. Prostatic Neoplasms / complications. Urologic Neoplasms / complications
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystectomy. Fatal Outcome. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Mastectomy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Radiotherapy, Adjuvant. Shock, Septic / complications. Spinal Neoplasms / complications. Spinal Neoplasms / diagnosis. Spinal Neoplasms / secondary. Urinary Diversion

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217994.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Satoh M, Wakabayashi O, Araya Y, Jinushi E, Yoshida F: [Autopsy case of von Recklinghausen's disease associated with lung cancer, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor]. Nihon Kokyuki Gakkai Zasshi; 2009 Sep;47(9):798-804
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autopsy case of von Recklinghausen's disease associated with lung cancer, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor].
  • Chest X-ray revealed multiple emphysematous bullae in both lungs and a tumor shadow in the right upper lobe.
  • The tumor was diagnosed as a non-small-cell lung cancer with direct invasion to the adjacent rib.
  • Autopsy revealed multiple emphysematous bullae, poorly differentiated adenosquamous cell carcinoma of the lung, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor.
  • This case suggests the possibility that von Recklinghausen's disease associated with emphysematous bullae is a risk factor for lung cancer.
  • Although von Recklinghausen's disease is reportedly associated with various malignant tumors, it is quite rare for von Recklinghausen's disease to be associated with triple non-neurogenic tumors.
  • [MeSH-major] Autopsy. Carcinoid Tumor / etiology. Carcinoma, Adenosquamous / etiology. Duodenal Neoplasms / etiology. Gastrointestinal Stromal Tumors / etiology. Lung Neoplasms / etiology. Neoplasms, Multiple Primary. Neurofibromatosis 1 / complications
  • [MeSH-minor] Fatal Outcome. Humans. Male. Middle Aged. Pulmonary Emphysema / complications. Pulmonary Emphysema / diagnosis. Pulmonary Emphysema / pathology. Risk Factors

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19827584.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


17. Kobashi Y, Mouri K, Fukuda M, Yoshida K, Miyashita N, Niki Y, Nakata M, Mikio O: [A case of pulmonary adenosquamous cell carcinoma with thin-wall cavities]. Nihon Kokyuki Gakkai Zasshi; 2005 Jan;43(1):59-62
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pulmonary adenosquamous cell carcinoma with thin-wall cavities].
  • A 68-year-old man was admitted to our hospital because of continuous cough of three months duration and for investigation of a thin-wall cavitary lesion (> 3 cm) in the right upper lung field.
  • A histological diagnosis of pulmonary adenocarcinoma was obtained by bronchoscopic examination, and he was transferred to the Department of Thoracic Surgery where a right upper lobectomy was performed.
  • Most of the surrounding cavity consisted of the components of a well differentiated squamous cell carcinoma with keratinization and slightly different components of a poorly differentiated adenocarcinoma with mucous production.
  • The final diagnosis was pulmonary adenosquamous cell carcinoma and the postoperative histological classification was T2N2M0 (Stage 3A) because of metastasis to the lymph nodes (#4 and #11).
  • Although squamous cell carcinoma has been reported to be the histological type, tending to form thin-wall cavities among patients with lung cancer reported to be squamous cell carcinoma, recently an increasing number of such cavities have been reported among patients with pulmonary adenocarcinoma.
  • Herein, we have reported a rare case of histological diagnosis of pulmonary adenosquamous cell carcinoma with cavity formation.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Lung / pathology. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15704455.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Sato T, Ito J, Shibuya H, Asano K, Watari T: Pulmonary adenosquamous carcinoma in a dog. J Vet Med A Physiol Pathol Clin Med; 2005 Dec;52(10):510-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary adenosquamous carcinoma in a dog.
  • A mass that developed in the lung of a 10-year-old mixed-breed dog was pathologically examined.
  • Histopathological examination showed papillary and tubular growth of glandular epithelium-like cells in some areas and growth of squamous cells arranged in nests in other areas, showing coexistence of adenocarcinoma and squamous cell carcinoma in a lung tumour.
  • Electron microscopically, the neoplastic cells of the adenocarcinoma component had features of glandular cells, with microvilli, numerous free ribosomes, large round secretory granules and intercellular desmosomes.
  • Non-keratinized squamous cells had tonofilaments and intercellular desmosomes.
  • These findings led to the diagnosis of primary adenosquamous carcinoma, which demonstrates phenotypic profiles characteristic of both epidermal keratinocytes and glandular epithelium.
  • [MeSH-major] Carcinoma, Adenosquamous / veterinary. Dog Diseases / pathology. Lung Neoplasms / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16300659.001).
  • [ISSN] 0931-184X
  • [Journal-full-title] Journal of veterinary medicine. A, Physiology, pathology, clinical medicine
  • [ISO-abbreviation] J Vet Med A Physiol Pathol Clin Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Kothari RK, Ghosh A, Bhattacharyya SK, Ghosh SK: Adenosquamous carcinoma of oral cavity: a case report. J Indian Med Assoc; 2007 Sep;105(9):531-2
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of oral cavity: a case report.
  • Histopathological examination of the biopsied material showed features suggestive of adenosquamous carcinoma, but CT-guided fine needle aspiration cytology from lung mass showed evidence of non-keratinising squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Adenosquamous / diagnosis. Mouth Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18338480.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


20. Okwuosa TM, Williams KA: "Mass-ive" infarction: case report and review of myocardial metastatic malignancies. J Nucl Cardiol; 2008 Sep-Oct;15(5):719-26
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cardiac metastases from lung cancer are rarely diagnosed ante mortem and usually cause no symptoms or signs.
  • In this case report cardiac metastasis from a primary adenosquamous cancer of the lung presented as myocardial infarction in a 61-year-old man.
  • His diagnosis was made and confirmed via multimodality imaging of the heart, which is also reviewed in depth.
  • [MeSH-major] Heart Neoplasms / secondary. Lung Neoplasms / pathology. Myocardial Infarction / pathology. Myocardium / pathology. Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18761275.001).
  • [ISSN] 1532-6551
  • [Journal-full-title] Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
  • [ISO-abbreviation] J Nucl Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


21. Carvalho L: Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry. Rev Port Pneumol; 2009 Nov-Dec;15(6):1101-19
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry.
  • The current state of molecular knowledge on lung cancer demands a histological classification which goes beyond small-cell and non-small-cell carcinoma to provide support for tailored therapy in aiding in understanding of the drugs currently available.
  • As diagnosis and follow-up in the vast majority of lung cancer cases is based on biopsies and cytology samples, Immunohistochemical Bronchial Pulmonary Carcinoma Classification (IBPCC) is necessary to reveal the raft of characteristics available.
  • The immunohistochemical panel clarifies the main morphology and cytology characteristics to maintain the leading histological types as squamous cell carcinoma (high weight molecular cytokeratins/HWMC), adenosquamous carcinoma (CK7, TTF1, HWMA), neuroendocrine carcinoma (Chrg, Syn, CD56, TTF1, Ki67), adenocarcinoma (CK7, CK20, TTF1) and bring the polymorphic and pleomorphic carcinomas under a single banner of pleomorphic carcinoma (Ck7, TTF1, HWMC, VMT, Desmin, Actin) which shelters large cell carcinomas and sarcomatoid carcinomas.
  • Lung cancer chemotherapy will still be based on platinum and gemcitabine for the near future and the IBPCC is a simple and efficient tool for streamlining the registration of lung cancer histological characteristics in biopsies and other reduced samples to support clinical evidence and trials.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Bronchial Neoplasms / classification. Bronchial Neoplasms / pathology. Lung Neoplasms / classification. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19859629.001).
  • [ISSN] 2172-6825
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] eng; por
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Portugal
  • [Number-of-references] 80
  •  go-up   go-down


22. Hu YY, Sun XR, Lin XP, Liang PY, Zhang X, Fan W: [Application of 18F-FDG PET/CT in cervical cancer with elevated levels of serum squamous cell carcinoma antigen during the follow-up]. Ai Zheng; 2009 Sep;28(9):994-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of 18F-FDG PET/CT in cervical cancer with elevated levels of serum squamous cell carcinoma antigen during the follow-up].
  • BACKGROUND AND OBJECTIVE: Accurate and early diagnosis of recurrence for cervical cancer after the treatment and aggressive salvage treatment could improve the prognosis of this disease.
  • Serum squamous cell carcinoma antigen (SCCAg) is the most commonly used tumor marker for the detection of asymptomatic recurrence of cervical cancer.
  • This study was to evaluate the application and value of (18)F-FDG PET/CT in cervical cancer with elevated of serum SCCAg level during the follow-up.
  • METHODS: Thirty-one patients with cervical cancer with elevated serum SCCAg level during the follow-up undergoing (18)F-FDG PET/CT in Sun Yat-sen University Cancer Center between August 2005 and November 2008 were entered into this retrospective study.
  • RESULTS: All 31 patients'pathological examination showed squamous cell carcinoma, including three adenosquamous carcinoma.
  • Of these 31 patients, three were confirmed to have local recurrent disease, 27 were verified to have metastatic disease and one was diagnosed as primary lung squamous cell carcinoma by pathological or clinical manifestations.
  • The total detection rate of PET/CT for malignancy was 100% (31/31); the diagnostic accuracy of PET/CT for recurrent cervical cancer was 96.8% (30/31).
  • CONCLUSIONS: An elevated level of SCCAg in cervical cancer during the follow-up indicates tumor recurrence.
  • [MeSH-major] Antigens, Neoplasm / blood. Carcinoma, Squamous Cell / radiography. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods. Serpins / blood. Uterine Cervical Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Carcinoma, Adenosquamous / blood. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Carcinoma, Adenosquamous / therapy. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Radiopharmaceuticals. Retrospective Studies. Tomography, X-Ray Computed


23. Gawrychowski J, Bruliński K, Malinowski E, Papla B: Prognosis and survival after radical resection of primary adenosquamous lung carcinoma. Eur J Cardiothorac Surg; 2005 Apr;27(4):686-92
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis and survival after radical resection of primary adenosquamous lung carcinoma.
  • OBJECTIVE: In order to evaluate the follow-up study of surgical treatment for primary adenosquamous lung carcinoma (ASC) we specified prognostic criteria, also in comparison with primary adenocarcinoma (AC).
  • CONCLUSIONS: Our findings indicate that in patients after radical operation for ASC, predominance for one of the histopathological components (adenous or squamous) within primary tumor is attended by worst prognosis.
  • Our study confirmed also that the prognosis of ASC of the lung was poorer than that of primary AC.
  • [MeSH-major] Carcinoma, Adenosquamous / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adenocarcinoma / surgery. Adult. Aged. Cause of Death. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15784375.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Rossi G, Sartori G, Cavazza A, Tamberi S: Mucoepidermoid carcinoma of the lung, response to EGFR inhibitors, EGFR and K-RAS mutations, and differential diagnosis. Lung Cancer; 2009 Jan;63(1):159-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of the lung, response to EGFR inhibitors, EGFR and K-RAS mutations, and differential diagnosis.
  • Mucoepidermoid carcinoma (MEC) of the lung needs to be carefully distinguished from other lung tumors with similar features, particularly from adenosquamous carcinoma, this latter tumor frequently showing EGFR mutations.
  • In contrast with the data reported by Han et al in the last July issue of Lung Cancer, neither EGFR nor K-RAS mutations were observed in MEC from caucasian patients.
  • [MeSH-major] Carcinoma, Mucoepidermoid / drug therapy. Carcinoma, Mucoepidermoid / genetics. Genes, ras. Lung Neoplasms / drug therapy. Lung Neoplasms / genetics. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Aged. Diagnosis, Differential. Epithelium / metabolism. Female. Humans. Keratins / metabolism. Mucin 5AC / metabolism. Mucins / metabolism. Mutation

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Lung Cancer. 2008 Jul;61(1):30-4 [18192072.001]
  • (PMID = 18992960.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucins; 68238-35-7 / Keratins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


25. Caldarella A, Crocetti E, Comin CE, Janni A, Pegna AL, Paci E: Gender differences in non-small cell lung cancer: a population-based study. Eur J Surg Oncol; 2007 Aug;33(6):763-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender differences in non-small cell lung cancer: a population-based study.
  • BACKGROUND: A retrospective study including all patients with non-small cell lung cancer carcinoma in a population-based registry was performed to characterize gender differences in lung cancer and to analyze the factors influencing prognosis in women.
  • METHODS: We retrieved through the Tuscan Cancer Registry (RTT) archive 2,523 lung tumor cases diagnosed during the period 1996-1998 in the provinces of Florence and Prato, central Italy.
  • We compared the prognosis within 464 non-small lung cancer women and 1,798 men in a population-based case series.
  • The influence of the following variables on postoperative survival were analyzed: age, cell type, pathologic T and N status, site of tumor and type of surgical resection.
  • RESULTS: The age at diagnosis was similar in women and in men.
  • Women were significantly more likely to have adenocarcinoma but less likely to have squamous cell carcinoma compared with men.
  • CONCLUSIONS: Lung cancer was more frequent in men than in women, but overall survival is similar.
  • Differences in lung cancer histology and rate of pneumonectomies were found between men and women.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / epidemiology. Lung Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Age Factors. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Squamous Cell / epidemiology. Female. Follow-Up Studies. Humans. Italy / epidemiology. Lymph Node Excision / statistics & numerical data. Male. Middle Aged. Neoplasm Staging. Pneumonectomy / statistics & numerical data. Population Surveillance. Prognosis. Registries. Retrospective Studies. Sex Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306497.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Ozdemir H, Tunçbilek G: Metastasis of carcinoma of the uterine cervix to the nasal dorsum. J Craniofac Surg; 2009 May;20(3):971-3
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of carcinoma of the uterine cervix to the nasal dorsum.
  • The nose is the most common site for cutaneous malignancies, and metastatic lesions in the skin of the nose are very rare, particularly metastasis of carcinoma of the uterine cervix.
  • We present the fourth patient with carcinoma of the uterine cervix who had cutaneous metastasis to the nose, indicating the dissemination of her carcinoma.
  • The patient had a diagnosis of carcinoma of the uterine cervix labeled as International Federation of Gynecology and Obstetrics stage IIB 30 months ago.
  • This patient showed a very poor prognosis after the appearance of a cutaneous metastasis of the cervical carcinoma, which is often perceived as a preterminal event, generally occurring in the later stages of the illness.
  • [MeSH-major] Carcinoma, Adenosquamous / secondary. Nose Neoplasms / secondary. Skin Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Fatal Outcome. Female. Humans. Lung Neoplasms / secondary. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19461347.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Tanaka T, Sekimura A, Tanaka H, Tonegawa K, Ogawa K, Haneda H: [Gallbladder metastasis of large cell lung cancer]. Kyobu Geka; 2009 Nov;62(12):1069-72
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gallbladder metastasis of large cell lung cancer].
  • A man, who received right upper lobectomy of the lung due to stage IIB large cell carcinoma 7 and half years ago, visited our hospital complaining of right upper abdominal pain.
  • Pathological diagnosis was adenosquamous cell carcinoma After 1 year and 4 months later, left adrenal gland tumor was found by CT scan, and the surgery was conducted.
  • Pathologically, it was diagnosed as metastasis from lung cancer.
  • By reevaluation of pathology of the gallbladder, the tumor was found to have similar component of resected lung cancer, suggesting the possibility of the tumor to be metastatic.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Gallbladder Neoplasms / secondary. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19894573.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


28. Achcar Rde O, Nikiforova MN, Dacic S, Nicholson AG, Yousem SA: Mammalian mastermind like 2 11q21 gene rearrangement in bronchopulmonary mucoepidermoid carcinoma. Hum Pathol; 2009 Jun;40(6):854-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammalian mastermind like 2 11q21 gene rearrangement in bronchopulmonary mucoepidermoid carcinoma.
  • The translocation t(11;19)(q21;p13) results in the gene fusion of mucoepidermoid carcinoma translocated 1-mammalian mastermind like 2 genes that is the major chromosomal abnormality observed in mucoepidermoid carcinomas of salivary glands but has not been studied in bronchopulmonary mucoepidermoid carcinoma.
  • To investigate the importance of the mammalian mastermind like 2 gene rearrangement and mucoepidermoid carcinoma translocated 1-mammalian mastermind like 2 fusion gene in bronchopulmonary mucoepidermoid carcinoma tumorigenesis and its differential diagnosis with primary pulmonary non-small-cell carcinomas, we evaluated the presence of the mammalian mastermind like 2 gene rearrangement and the mucoepidermoid carcinoma translocated 1-mammalian mastermind like 2 fusion in formalin-fixed, paraffin-embedded tissue sections from 17 adult bronchopulmonary mucoepidermoid carcinoma, 16 adenosquamous carcinomas, 24 squamous cell carcinomas, and 41 primary adenocarcinomas by fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction.
  • We detected mammalian mastermind like 2 gene rearrangement by fluorescence in situ hybridization analysis in 13 (77%) of 17 bronchopulmonary mucoepidermoid carcinoma cases (10 of 10 being low grade and 3 of 7 being high grade).
  • Reverse transcriptase polymerase chain reaction analysis confirmed positive fluorescence in situ hybridization results in 6 (43%) of 14 mucoepidermoid carcinoma cases.
  • None of the squamous, adenosquamous, or adenocarcinoma cases revealed the mammalian mastermind like 2 gene rearrangement by fluorescence in situ hybridization, and the mucoepidermoid carcinoma translocated 1-mammalian mastermind like 2 fusion product by reverse transcriptase polymerase chain reaction was not identified specifically in our adenosquamous carcinoma cases.
  • In conclusion, our study demonstrates that mammalian mastermind like 2 gene rearrangement and mucoepidermoid carcinoma translocated 1-mammalian mastermind like 2 fusion product can be detected by fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction analysis performed on low- and high-grade primary bronchopulmonary mucoepidermoid carcinoma and can be used to help discriminate low- and high-grade mucoepidermoid carcinoma from adenocarcinoma, adenosquamous carcinoma, and squamous cell carcinoma mimics in histologically challenging cases.
  • [MeSH-major] Bronchial Neoplasms / genetics. Carcinoma, Mucoepidermoid / genetics. DNA-Binding Proteins / genetics. Lung Neoplasms / genetics. Nuclear Proteins / genetics. Oncogene Proteins, Fusion / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adenosarcoma / genetics. Adenosarcoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Female. Gene Fusion. Gene Rearrangement. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Translocation, Genetic

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269006.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRTC1 protein, human; 0 / DNA-Binding Proteins; 0 / MAML2 protein, human; 0 / MECT1-MAML2 fusion protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / Transcription Factors
  •  go-up   go-down


29. Mori T, Nomori H, Ikeda K, Kawanaka K, Shiraishi S, Katahira K, Yamashita Y: Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography. J Thorac Oncol; 2008 Apr;3(4):358-64
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • FDG uptake of each lesion was quantitatively measured by a contrast ratio of standard uptake value (SUV-CR) between the lesions and contralateral lung.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Lung Neoplasms / diagnosis. Positron-Emission Tomography / methods. Solitary Pulmonary Nodule / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Squamous Cell / diagnosis. Diagnostic Imaging. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Prognosis. Prospective Studies. ROC Curve. Sensitivity and Specificity. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379353.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


30. Manxhuka-Kerliu S, Telaku S, Ahmetaj H, Baruti A, Loxha S, Kerliu A: Colorectal cancer: prognostic values. Bosn J Basic Med Sci; 2009 Feb;9(1):19-24
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal cancer: prognostic values.
  • After lung cancer colorectal cancer (Cc) is ranked the second, as a cause of cancer-related death.
  • There were investigated 149 cases of resection specimen with colorectal cancer, which were fixed in buffered neutral formalin and embedded in paraffin.
  • Adenocarcinoma was the most frequent histological type found in 85,90% of cases, in 60,94% of males and 39,06% of females; squamous cell carcinoma in 7,38%, in 63,63% of males and 36,36% of females; mucinous carcinoma in 4,68%, in 57,15% of males and 42,85% of females; while adenosquamous carcinoma, undifferentiated carcinoma and carcinoma in situ in 0,71% of cases each.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19284390.001).
  • [ISSN] 1512-8601
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


31. Kaneda M, Tarukawa T, Watanabe F, Adachi K, Sakai T, Nakabayashi H: Clinical features of primary lung cancer adjoining pulmonary bulla. Interact Cardiovasc Thorac Surg; 2010 Jun;10(6):940-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of primary lung cancer adjoining pulmonary bulla.
  • A few investigators have suggested a possible association between lung cancer and a pulmonary bulla.
  • Five hundred and forty-five cases with primary lung cancer were studied retrospectively by re-evaluation of their chest computed tomography (CT)-scans.
  • Cancer adjoined a bulla in 19 cases.
  • Bulla/cancer incidence was 3.5%.
  • In comparison with the control group, a ratio of squamous cell carcinoma (SCC) and large cell carcinoma was significantly high (P<0.05) and differentiation of the carcinoma was poor (P<0.001).
  • Although the pathological staging and lung function data revealed no statistical difference, the survival curve of bulla/cancer group was significantly worse (P<0.01).
  • Primary lung cancer adjoining pulmonary bulla tends to be poor in prognosis, even if it was small in size.
  • [MeSH-major] Blister / diagnosis. Carcinoma / diagnosis. Lung / pathology. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Large Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cell Differentiation. Humans. Incidence. Japan / epidemiology. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Respiratory Function Tests. Retrospective Studies. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20299444.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, Nakanishi Y, Tsuchiya R, Shimokata K, Inoue H, Nukiwa T, Miyaoka E, Japanese Joint Committee of Lung Cancer Registry: A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol; 2008 Jan;3(1):46-52
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers.
  • PURPOSE: The validation of tumor, node, metastasis staging system in terms of prognosis is an indispensable part of establishing a better staging system in lung cancer.
  • METHODS: In 2005, 387 Japanese institutions submitted information regarding the prognosis and clinicopathologic profiles of patients who underwent pulmonary resections for primary lung neoplasms in 1999 to the Japanese Joint Committee of Lung Cancer Registry.
  • The data of 13,010 patients with only lung carcinoma histology (97.6%) were analyzed in terms of prognosis and clinicopathologic characteristics.
  • For the small cell histology (n = 390), the 5-year survival rates according to clinical (c) and pathologic (p) stages were as follows: 58.8% (n = 161) and 58.3% (n = 127) for IA, 58.0% (n = 77) and 60.2% (n = 79) for IB, 47.1% (n = 17) and 40.6% (n = 29) for IIA, 25.3% (n = 38) and 41.1% (n = 29) for IIB, 29.0% (n = 61) and 28.3% (n = 60) for IIIA, 36.3% (n = 19) and 34.6% (n = 40) for IIIB, and 27.8% (n = 12) and 30.8% for IV (n = 13).
  • For the non-small cell histology (n = 12,620), the 5-year survival rates according to c-stage and p-stage were as follows: 77.3% (n = 5642) and 83.9% (n = 4772) for IA, 59.8% (n = 3081) and 66.3% (n = 2629) for IB, 54.1% (n = 205) and 61.0% (n = 361) for IIA, 43.9% (n = 1227) and 47.4% (n = 1330) for IIB, 38.3% (n = 1628) and 32.8% (n = 1862) for IIIA, 32.6% (n = 526) and 29.6% (n = 1108) for IIIB, and 26.5% (n = 198) and 23.1% (n = 375) for IV.
  • Adenocarcinoma, female gender, and age less than 50 years were significant favorable prognostic factors.
  • CONCLUSION: This large registry study provides benchmark prognostic statistics for lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Registries
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / pathology. Aged. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / pathology. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / pathology. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Female. Follow-Up Studies. Hospitals, Teaching. Humans. Japan. Male. Middle Aged. Models, Biological. Neoplasm Staging. Prognosis. Reproducibility of Results. Retrospective Studies. Surveys and Questionnaires. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166840.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Katz SL, Das P, Ngan BY, Manson D, Pappo AS, Sweezey NB, Solomon MP: Remote intrapulmonary spread of recurrent respiratory papillomatosis with malignant transformation. Pediatr Pulmonol; 2005 Feb;39(2):185-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extension into lung parenchyma occurs in less than 1% of patients and has a low risk of malignant transformation.
  • We describe a case of recurrent respiratory papillomatosis with extensive parenchymal involvement and adenosquamous carcinoma in a 14-year-old girl.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Cell Transformation, Neoplastic. Laryngeal Neoplasms / pathology. Lung Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Papilloma / pathology
  • [MeSH-minor] Adolescent. Biopsy, Needle. Combined Modality Therapy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Radiography, Thoracic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15532092.001).
  • [ISSN] 8755-6863
  • [Journal-full-title] Pediatric pulmonology
  • [ISO-abbreviation] Pediatr. Pulmonol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Jin X, Zhang J, Gao Y, Ding K, Wang N, Zhou D, Jen J, Cheng S: Relationship between mitochondrial DNA mutations and clinical characteristics in human lung cancer. Mitochondrion; 2007 Sep;7(5):347-53
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between mitochondrial DNA mutations and clinical characteristics in human lung cancer.
  • However, roles of mutations and polymorphisms in some diseases are among heated debate, especially for cancer.
  • To investigate the possible role of mtDNA mutations in lung cancer, we sequenced complete mtDNA of lung cancer tissues, corresponding normal (i.e., non-cancerous) lung tissues, and peripheral blood samples from 55 lung cancer patients and examined the relationship between mtDNA mutations or polymorphisms and clinical parameters.
  • There was no association of incidence of specific mtDNA mutation or polymorphism with patients' gender, age at diagnosis, smoking history, tumor type or tumor stage (P>0.05).
  • This study revealed a variety of mtDNA mutations and mtDNA polymorphisms in human lung cancer, some of which might be involved in human lung carcinogenesis.
  • [MeSH-major] DNA, Mitochondrial / genetics. Lung Neoplasms / genetics. Polymorphism, Genetic
  • [MeSH-minor] Adenocarcinoma / genetics. Aged. Carcinoma, Adenosquamous / genetics. Carcinoma, Small Cell / genetics. Carcinoma, Squamous Cell / genetics. Female. Humans. Male. Middle Aged. Point Mutation

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17707697.001).
  • [ISSN] 1567-7249
  • [Journal-full-title] Mitochondrion
  • [ISO-abbreviation] Mitochondrion
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  •  go-up   go-down


35. Yi L, Wang Y: [Mixed prostatic carcinoma: a report of 5 patients and literature review]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jul;34(7):646-50
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mixed prostatic carcinoma: a report of 5 patients and literature review].
  • OBJECTIVE: To improve the awareness of rare mixed prostatic carcinoma.
  • METHODS: We reviewed the clinical data of 5 patients with prostatic mixed tumor and relevant literature to explore diagnosis and treatment for it.
  • RESULTS: Patient 1 with mixed small cell carcinoma and adenocarcinoma of the prostate who underwent transurethral electrovaporization of the prostate (TUVP) and flumamide therapy died of lung metastasis 7 months later.
  • Patient 2 with mixed small cell carcinoma and adenocarcinoma of the prostate who underwent TUVP and bilateral testicular resection died of lung metastasis 10 months later.
  • Patient 3 with adenosquamous carcinoma of the prostate who underwent TUVP, radiation therapy and flumamide therapy died of multiple organ failure 8 months later because of the lung, liver, and multiple bone metastasis.
  • Patient 4 with prostatic adenosquamous carcinoma who underwent cystoprostatectomy combined with urinary diversion has already survived for 1 year.
  • Patient 5 with prostatic carcinosarcoma who underwent cystoprostatectomy, urinary diversion, pelvic lymphadenectomy, and radiation therapy died of lung metastasis 13 months later.
  • CONCLUSION: Mixed prostatic carcinoma is quite aggressive with bad prognosis.
  • Its diagnosis relies on detailed pathological examination and immunohistochemical techniques.
  • Patients with prostate adenocarcinoma should be followed up timely after endocrine treatment or radiotherapy.
  • Radical surgery is most effective for mixed prostatic carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Adenosquamous / pathology. Carcinoma, Small Cell / pathology. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648679.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down


36. de Jong WK, Schaapveld M, Blaauwgeers JL, Groen HJ: Pulmonary tumours in the Netherlands: focus on temporal trends in histology and stage and on rare tumours. Thorax; 2008 Dec;63(12):1096-102
MedlinePlus Health Information. consumer health - Rare Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: All tumours originating from the trachea, bronchus and lung recorded in the Netherlands Cancer Registry were included.
  • Based on ICD-O morphology codes, five major subgroups were constructed: squamous carcinoma (SC), adenocarcinoma (AC), large cell (undifferentiated) carcinoma (LC), small cell lung cancer (SCLC) and other (including uncommon tumours).
  • Since 1996, a stage shift was observed with fewer patients in stage I and more patients in stage IV at diagnosis.
  • The incidence of adenosquamous carcinoma decreased from 0.6 to 0.29/100 000 (p<0.001).
  • The incidence of non-smoking-related uncommon tumours remained constant.
  • [MeSH-major] Bronchial Neoplasms / epidemiology. Lung Neoplasms / epidemiology. Rare Diseases / epidemiology. Tracheal Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adolescent. Adult. Aged. Carcinoma, Large Cell / epidemiology. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Netherlands / epidemiology. Small Cell Lung Carcinoma / epidemiology. Small Cell Lung Carcinoma / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18678702.001).
  • [ISSN] 1468-3296
  • [Journal-full-title] Thorax
  • [ISO-abbreviation] Thorax
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


37. Bossuyt V, Fadare O, Martel M, Ocal IT, Burtness B, Moinfar F, Leibl S, Tavassoli FA: Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation. Int J Surg Pathol; 2005 Oct;13(4):319-27
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation.
  • This study assessed EGFR expression in breast carcinomas with squamous differentiation.
  • The immunohistochemical (IHC) expression of EGFR was evaluated in 39 breast carcinomas with squamous differentiation (30 pure squamous, 6 adenosquamous, 3 carcinosarcomas) by use of the pharmDx assay (clone 2-18C9, DakoCytomation).
  • Cases were considered positive if at least 10% of the cells showed 1+ positivity in the squamous component.
  • Squamous differentiation was confirmed with IHC for CK5-6 (clone D5/16B4, DakoCytomation).
  • At the time of initial diagnosis, 3 patients had distant metastasis.
  • EGFR-positive tumor cells (showing squamous morphology) were also found in 1 bone, 1 lung, and 8 of 11 lymph node metastases available for evaluation.
  • All 11 lymph nodes showed squamous differentiation.
  • Nine of 280 (3%) of lymph node-positive invasive carcinomas on the tissue microarray were EGFR+; review of the initial diagnostic slides failed to reveal squamous features in all but 1 of the 9 EGFR+ tumors.
  • Breast carcinomas with squamous differentiation are a distinct subgroup of breast tumors with a very high frequency of EGFR positivity.
  • [MeSH-major] Breast Neoplasms / chemistry. Carcinoma, Squamous Cell / chemistry. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adult. Aged. Bone Neoplasms / chemistry. Bone Neoplasms / pathology. Bone Neoplasms / secondary. Carcinoma, Adenosquamous / chemistry. Carcinoma, Adenosquamous / pathology. Carcinosarcoma / chemistry. Carcinosarcoma / pathology. Cell Differentiation. Follow-Up Studies. Humans. Immunohistochemistry. Keratins / analysis. Lung Neoplasms / chemistry. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Estrogen / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Surg Pathol. 2006 Jul;14(3):268; author reply 269 [16959717.001]
  • (PMID = 16273187.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 68238-35-7 / Keratins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


38. Robledo-Ogazón F, Vargas-Rivas A, Hernández-Ramírez DA, Castellanos-Juárez JC: [Congenital diaphragmatic adult hernia. Case report]. Cir Cir; 2008 Jan-Feb;76(1):61-4
MedlinePlus Health Information. consumer health - Chest Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Hernia diafragmática congénita en el adulto. Informe de un caso.
  • Diagnosis is incidental or when it becomes symptomatic.
  • Our objective was to offer the general surgeon a differential diagnosis for presence of noncardiac thoracic pain in the adult.
  • Primary repair of the diaphragm and cholecystectomy were performed, confirming gallbladder cancer.
  • It is important that the surgeon establishes an etiological diagnosis in order to offer appropriate treatment.
  • CONCLUSIONS: Congenital diaphragmatic hernia in the adult is rarely suspected in the differential diagnosis of noncardiac thoracic pain.
  • The surgeon must keep this in mind, especially in patients of advanced age, even when cardiac and/or gastrointestinal diagnosis is confirmed.
  • [MeSH-minor] Age of Onset. Aged. Carcinoma, Adenosquamous / complications. Carcinoma, Adenosquamous / radiography. Carcinoma, Adenosquamous / surgery. Cholecystectomy. Cholelithiasis / complications. Cholelithiasis / surgery. Cough / etiology. Diagnostic Errors. Dyspepsia / diagnosis. Female. Gallbladder Neoplasms / complications. Gallbladder Neoplasms / radiography. Gallbladder Neoplasms / surgery. Gastroesophageal Reflux / etiology. Heart Diseases / diagnosis. Hernia, Diaphragmatic / complications. Hernia, Diaphragmatic / diagnosis. Hernia, Diaphragmatic / epidemiology. Humans. Incidental Findings. Lung Diseases / diagnosis. Tomography, X-Ray Computed


39. Gao YS, Zhang DC, He J, Sun KL, Zhang DW, Zhang RG: [Diagnosis and surgical treatment for stage I non-small-cell lung cancer]. Zhonghua Zhong Liu Za Zhi; 2005 Jan;27(1):52-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and surgical treatment for stage I non-small-cell lung cancer].
  • OBJECTIVE: To evaluate the results of surgery and the diagnosis of stage I non-small-cell lung cancer (NSCLC).
  • The 5-year survival rates for patients with squamous-cell carcinoma, adenocarcinoma, adenosquamous and alveolar-cell carcinoma were 73.3%, 55.3%, 52.2%, 71.7%, respectively.
  • The 1-, 3-, 5-year survival rates for T1N0 were 95.0%, 83.2%, 74.3% whereas those of T2N0 lung lesions were 90.8%, 75.9%, 59.9% (P < 0.05).
  • CONCLUSION: The 5-year survival rate of pathologic stage I non-small-cell lung cancer is 66.1%.
  • The outcome of patients with squamous-cell carcinoma (73.3%) is similar to that of alveolar-cell carcinoma (71.7%) which, however, is better than that of adenocarcinoma (55.3%) or adenosquamouscarcinoma (52.5%).
  • Regular lobectomy plus radical mediastinal lymph node dissection is the appropriate management for stage I non-small-cell lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Lymph Node Excision. Pneumonectomy / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771801.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


40. Ventsiavichius V, Tsitsenas S, Tikuĭshis R: [Potentialities of surgical treatment for concomitance of pulmonary tuberculosis and lung cancer]. Probl Tuberk Bolezn Legk; 2007;(5):32-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Potentialities of surgical treatment for concomitance of pulmonary tuberculosis and lung cancer].
  • The paper deals with the important problem of pulmonary surgery--the capacities of surgical treatment in concomitance of pulmonary tuberculosis and lung cancer.
  • In 1990 to 2002, the Santarishkes Republican Tuberculosis and Lung Diseases Hospital and the Department of Thoracic Surgery and Oncology, Vilnius University Cancer Institute operated on 2218 patients with lung cancer, of them 46 (2.1%) were diagnosed as having concomitance of lung cancer and tuberculosis.
  • The diagnosis of central and peripheral lung cancer was established in 37 (80.4%) and 9 (19.6%) patients, respectively.
  • Histology revealed squamous-cell tumors in 24 (52.2%) patients, adenocarcinoma in 10 (21.7%), and adenosquamous-cell carcinomas in 12 (26.1%) patients.
  • Surgery is the method of choice in the treatment of concomitance of pulmonary tuberculosis and lung cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / complications. Lung Neoplasms / surgery. Tuberculosis, Pulmonary / complications

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17598460.001).
  • [ISSN] 1728-2993
  • [Journal-full-title] Problemy tuberkuleza i bolezneĭ legkikh
  • [ISO-abbreviation] Probl Tuberk Bolezn Legk
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


41. Cappello F, Di Stefano A, David S, Rappa F, Anzalone R, La Rocca G, D'Anna SE, Magno F, Donner CF, Balbi B, Zummo G: Hsp60 and Hsp10 down-regulation predicts bronchial epithelial carcinogenesis in smokers with chronic obstructive pulmonary disease. Cancer; 2006 Nov 15;107(10):2417-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The relation between smoking, chronic obstructive pulmonary disease (COPD), and lung cancer (LC) is an open field of investigation.
  • A higher frequency of adenocarcinoma has been reported in patients with COPD.
  • Heat shock proteins (Hsps) are implicated in tumoral cell growth and differentiation.
  • The aim of the present study was to investigate the expression of Hsp60 and Hsp10 in bronchial biopsies from smokers with COPD and in 10 lung cancer patients and to evaluate the association between Hsps expression and carcinogenetic steps of LC.
  • METHOD: An immunohistochemical study was performed for Hsp60 and Hsp10 in bronchial biopsies from 35 COPD (postbronchodilator forced expiratory volume in 1 second [FEV(1)]: 53 +/- 19% [mean +/- SD]) patients with a history of smoking (53 +/- 34 pack/years) and in 10 patients with adenocarcinoma or adenosquamous carcinoma (ASC).
  • RESULTS.: In smokers with COPD, 10 out of 35 patients had a normal bronchial epithelium (NBE), 12 showed basal cell hyperplasia (BCH), 5 squamous metaplasia (SM), and 8 dysplasia (Dy).
  • CONCLUSIONS: The loss of Hsp60 and Hsp10 immunopositivity is related to the development and progression of bronchial cancer in smokers with COPD.
  • [MeSH-major] Carcinoma, Bronchogenic / diagnosis. Chaperonin 10 / metabolism. Chaperonin 60 / metabolism. Lung Neoplasms / diagnosis. Pulmonary Disease, Chronic Obstructive / complications. Smoking / adverse effects
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Aged. Blotting, Western. Carcinoma, Adenosquamous / complications. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / pathology. Disease Progression. Down-Regulation. Humans. Middle Aged. Prognosis. Respiratory Mucosa / pathology


42. Wang LJ, Greaves WO, Sabo E, Noble L, Tavares R, Ng T, DeLellis RA, Resnick MB: GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors. Appl Immunohistochem Mol Morphol; 2009 Dec;17(6):505-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors.
  • Gross cystic disease fluid protein (GCDFP-15) is currently used as an immunohistochemical marker of breast cancer, whereas thyroid transcription factor (TTF-1) is commonly used as a marker of primary lung neoplasms.
  • Traditionally, a GCDFP-15+/TTF-1- immunohistochemical profile in lung tumors has been considered as highly suggestive of metastatic carcinoma of the breast.
  • Here, we investigated the expression of GCDFP-15 and TTF-1 on a tissue microarray consisting of 381 primary lung carcinomas.
  • Seventeen tumors (4.5%) were positive for GCDFP-15, including 11 of 186 (5.9%) adenocarcinomas, 1 of 97 (1%) squamous cell carcinomas, 1 of 23 (4.3%) carcinoid tumors, 2 of 47 (4.3%) large cell carcinomas, and 2 of 17 (11.8%) adenosquamous carcinomas.
  • Our study confirms that a small subset of primary lung adenocarcinomas exhibits a GCDFP-15 positive phenotype.
  • Thus a GCDFP-15 positive/TTF-1 negative phenotype may not be indicative of metastatic breast carcinoma in every case.
  • It is critical that pathologists be aware of this phenotypic subset of lung adenocarcinomas, especially when faced with small tissue or cytologic samples.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620839.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / Glycoproteins; 0 / PIP protein, human; 0 / TTF1 protein, human
  •  go-up   go-down


43. Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Takada S, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y, Mano H: Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res; 2008 Oct 15;14(20):6618-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: EML4-ALK is a fusion-type protein tyrosine kinase that is generated by inv(2)(p21p23) in the genome of non-small cell lung cancer (NSCLC).
  • EXPERIMENTAL DESIGN: Primers were designed to detect all possible in-frame fusions of EML4 to exon 20 of ALK, and a single-tube multiplex RT-PCR assay was done with total RNA from 656 solid tumors of the lung (n = 364) and 10 other organs.
  • RESULTS: From consecutive lung adenocarcinoma cases (n = 253), we identified 11 specimens (4.35%) positive for fusion transcripts, 9 of which were positive for the previously identified variants 1, 2, and 3.
  • No fusion transcripts were detected for other types of lung cancer (n = 111) or for tumors from 10 other organs (n = 292).
  • CONCLUSIONS: These data reinforce the importance of accurate diagnosis of EML4-ALK-positive tumors for the optimization of treatment strategies.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Exons / genetics. Oncogene Proteins, Fusion / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / genetics. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / genetics. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / genetics. Cell Transformation, Neoplastic. Chromosome Inversion. DNA Primers / chemistry. Gene Rearrangement. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Lung Neoplasms / diagnosis. Lung Neoplasms / genetics. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18927303.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / EML4-ALK fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / RNA, Neoplasm
  •  go-up   go-down


44. Matsuoka H, Okada M, Sakamoto T, Tsubota N: Complications and outcomes after pulmonary resection for cancer in patients 80 to 89 years of age. Eur J Cardiothorac Surg; 2005 Sep;28(3):380-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complications and outcomes after pulmonary resection for cancer in patients 80 to 89 years of age.
  • OBJECTIVE: Patients 80 years or older often present with potentially resectable cases of non-small cell lung cancer.
  • METHODS: From April 1997 through March 2004, 40 consecutive patients with non-small cell lung cancer who were 80-88 years of age underwent complete resection of their tumors, as confirmed pathologically.
  • The histopathologic diagnosis was adenocarcinoma in 22 patients, squamous cell carcinomas in 11, large cell carcinomas in 4, adenosquamous cell carcinomas in 2, and neuro-endocrine cell carcinoma in 1.
  • Eight patients had non-lethal complications (20%), including five with cardiopulmonary complications (parenchymal air leaks persisting for more than 7 days in two patients, interstitial pneumonia in one, bacterial pneumonia in one, and moderate arrhythmias in one) and three with minor complications (depression or confusion).
  • CONCLUSIONS: Advanced age is not a contraindication to curative resection in patients 80-89 years of age with stage I non-small cell lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Patient Selection
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Age Factors. Aged, 80 and over. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / surgery. Carcinoma, Neuroendocrine / mortality. Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cardiothorac Surg. 2005 Dec;28(6):912-3; author reply 913 [16275004.001]
  • [CommentIn] Eur J Cardiothorac Surg. 2007 Jan;31(1):141; author reply 141-2 [17126024.001]
  • [CommentIn] Eur J Cardiothorac Surg. 2005 Dec;28(6):911-2; author reply 912 [16242942.001]
  • (PMID = 16054820.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


45. Zhang H, Zhao Q, Chen Y, Wang Y, Gao S, Mao Y, Li M, Peng A, He D, Xiao X: Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas. Thorax; 2008 Apr;63(4):352-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas.
  • This study was undertaken to investigate the possibility that overexpression of S100A7 protein might be detected in the sera of patients with lung cancer.
  • METHODS: RNA and protein levels of S100A7 were examined in 60 pairs of frozen lung cancer tissues by RT-PCR and western blot.
  • The specific expression of this protein and its cellular distribution were investigated in 145 paraffin embedded lung cancer samples, six benign lung disease and 21 normal lung tissues by immunohistochemistry.
  • The S100A7 protein level was further analysed in serum from 112 patients with lung cancer, 20 with benign lung diseases and 31 healthy individuals by ELISA.
  • RESULTS: Specific expression of both S100A7 mRNA and protein was found in squamous cell carcinomas, adenosquamous carcinomas and large cell lung carcinomas, whereas neither was detected in adenocarcinomas or paired non-cancerous lung tissues.
  • Further immunohistochemical analysis identified positive staining of S100A7 only in squamous cell carcinomas and large cell lung carcinomas, but not in other subtypes of lung cancer and normal lung tissues.
  • Weak expression was also found in the inflammatory cells of benign lung diseases.
  • Our most important finding is that elevated S100A7 protein could be detected in the sera of patients with squamous cell carcinomas.
  • CONCLUSION: S100A7 was only expressed in squamous cell carcinomas and large cell lung carcinomas and an increase in the level of S100A7 protein in serum may serve as a potential marker for lung cancer diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Calcium-Binding Proteins / metabolism. Carcinoma, Large Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Lung Neoplasms / diagnosis. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18364444.001).
  • [ISSN] 1468-3296
  • [Journal-full-title] Thorax
  • [ISO-abbreviation] Thorax
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Neoplasm Proteins; 0 / S100 Proteins; 0 / S100A7 protein, human
  •  go-up   go-down


46. Picozzi G, Paci E, Lopez Pegna A, Bartolucci M, Roselli G, De Francisci A, Gabrielli S, Masi A, Villari N, Mascalchi M: Screening of lung cancer with low dose spiral CT: results of a three year pilot study and design of the randomised controlled trial ''Italung-CT''. Radiol Med; 2005 Jan-Feb;109(1-2):17-26
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening of lung cancer with low dose spiral CT: results of a three year pilot study and design of the randomised controlled trial ''Italung-CT''.
  • PURPOSE: To report the results of a three-year observational pilot study of lung cancer screening with low dose computed tomography (CT) and to present the study design of a randomised clinical trial named as ''Italung-CT''.
  • Indeterminate nodules were managed according to the recommendations of the Early Lung Cancer Action Project.
  • One (1.6%) prevalent lung cancer (adenosquamous carcinoma) and one (2.2%) incident lung cancer (small cell cancer at the first annual examination) were observed, as well as a pulmonary localisation of Hodgkin's lymphoma (at the second annual test).
  • In addition, one subject underwent lung surgery for a chondromatous hamartoma.
  • [MeSH-major] Lung Neoplasms / radiography. Tomography, Spiral Computed
  • [MeSH-minor] Female. Humans. Lung / radiography. Male. Middle Aged. Pilot Projects. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15729183.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


47. Mazza E, Maddau C, Ricciardi A, Falchini M, Matucci M, Ciarpallini T: On-site evaluation of percutaneous CT-guided fine needle aspiration of pulmonary lesions. A study of 321 cases. Radiol Med; 2005 Sep;110(3):141-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Three hundred and twenty-one FNAs of lung lesions were performed in 312 patients (218 males, 94 females; age range: 20-86 years; mean age: 66 yrs).
  • Smears were prepared in the Radiology Department and stained using a quick method by a cytopathologist: the sample adequacy was assessed and, if possible, a preliminary diagnosis was made.
  • CONCLUSIONS: CT guided aspiration cytology can be a safe and fast procedure for lung nodule characterisation.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Needle / methods. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / pathology. Lung / pathology. Lung Neoplasms / pathology. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cytodiagnosis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Pneumothorax / radiography. Radiography, Thoracic

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16200036.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


48. Toyooka S, Yatabe Y, Tokumo M, Ichimura K, Asano H, Tomii K, Aoe M, Yanai H, Date H, Mitsudomi T, Shimizu N: Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung. Int J Cancer; 2006 Mar 15;118(6):1588-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Genes, ras / genetics. Lung Neoplasms / pathology. Mutation. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16187277.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


49. Tudor A, Sestan B, Jonjic N, Miletic D, Hadzisejdic I, Prpic T, Rakovac I: Solitary metastasis of the patella in the differential diagnosis of anterior knee pain. West Indian Med J; 2010 Jan;59(1):110-2
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary metastasis of the patella in the differential diagnosis of anterior knee pain.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Adenosquamous / secondary. Lung Neoplasms / pathology. Pain / diagnosis. Patella / pathology
  • [MeSH-minor] Aged, 80 and over. Biopsy. Diagnosis, Differential. Diagnostic Imaging. Humans. Male

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20931928.001).
  • [ISSN] 0043-3144
  • [Journal-full-title] The West Indian medical journal
  • [ISO-abbreviation] West Indian Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Jamaica
  •  go-up   go-down


50. Lin H, Ma YY, Huang CC, Moh JS, Tsai YM, Changchien CC: Oropharyngeal recurrence after bronchial washing for a lung mass in a patient with cervical cancer. Acta Obstet Gynecol Scand; 2006;85(8):1015-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oropharyngeal recurrence after bronchial washing for a lung mass in a patient with cervical cancer.
  • [MeSH-major] Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / secondary. Lung Neoplasms / secondary. Oropharyngeal Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Bronchoalveolar Lavage. Fatal Outcome. Female. Human papillomavirus 18 / isolation & purification. Humans. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / virology






Advertisement